中国全科医学

• •

桂枝甘草汤通过PPARγ/UCP1信号通路促进冷暴露小鼠非颤抖性产热的机制研究

沈泽旭1,李想1,闫承慧2,任天舒1,邢波1,曲莹莹1,姚冬1,许子华1*,韩雅玲2*,赵庆春1*   

  1. 1.110840 辽宁省沈阳市,北部战区总医院临床药学科 2.110840 辽宁省沈阳市,北部战区总医院心血管内科
  • 收稿日期:2025-07-09 修回日期:2025-10-14 接受日期:2025-11-14
  • 通讯作者: 赵庆春,主任药师 韩雅玲,主任医师 许子华:副主任药师

Mechanistic Study of Guizhi-Gancao Decoction in Promoting Non-shivering Thermogenesis via the PPARγ/UCP1 Signaling Pathway in Cold-Exposed Mice

SHEN Zexu1, LI Xiang1, YAN Chenghui2, REN Tianshu1, XING Bo1, QU Yingying1, YAO Dong1, XU Zihua1*, HAN Yaling2*, ZHAO Qingchun1*   

  1. 1.Department of Clinical Pharmacy, General Hospital of Northern Theatre Command, Shenyang 110840, China 2.Department of Cardiology, General Hospital of Northern Theatre Command, Shenyang 110840, China
  • Received:2025-07-09 Revised:2025-10-14 Accepted:2025-11-14
  • Contact: ZHAO Qingchun, Chief pharmacist HAN Yaling, Chief physician Xu Zihua, Deputy Chief pharmacist

摘要: 背景 桂枝甘草汤(GGD)是祖国传统医学中的著名方剂,由桂枝(RC)和甘草(RG)两味药材组成,具有补助心阳、生阳化气之功效,但其抗寒作用与机制尚不明确。目的 研究桂枝甘草汤的抗寒活性,鉴定其主要成分,并探究其产热机制。方法 实验时间为2020—2023年。根据《伤寒论》记载的制备方法制作桂枝甘草汤。将小鼠随机分为6组:空白对照组(无寒冷暴露)、冷暴露模型组、米格列醇组(50 mg/kg,寒冷暴露)和桂枝甘草汤低、中、高剂量组(1、2、4 g/kg,冷暴露),每组10只。给药14 d后进行急性冷暴露(-20℃,60 min)与寒冷适应后暴露(-20℃,120 min)实验,采用体温计和红外热像仪检测核心体温及体表温度;通过跑道穿越时间与游泳距离评估运动能力;测量尾部非坏死长度评价外周循环保护作用。使用高效液相色谱-四极杆飞行时间质谱法(HPLC-Q-TOF-MS)鉴定桂枝甘草汤的主要成分,利用网络药理学分析关键化合物、靶点和通路,并通过蛋白质免疫印迹法、线粒体膜电位及ATP含量测定进行机制验证。结果 急性寒冷暴露60 min后,桂枝甘草汤中、高剂量组小鼠核心体温高于冷暴露模型组(P0.05)。冷暴露后,跑道实验中,冷暴露模型组和米格列醇组跑道穿越时间长于空白对照组,米格列醇组及桂枝甘草汤各剂量组短于冷暴露模型组,桂枝甘草汤各剂量组短于米格列醇组(P0.05)。米格列醇组及桂枝甘草汤各剂量组小鼠尾部非坏死长度长于冷暴露模型组(P<0.05)。HPLC-Q-TOF-MS共鉴定出桂枝甘草汤中49种成分;网络药理学分析显示,过氧化物酶体增殖物激活受体γ(PPARγ)、解偶联蛋白1(UCP1)和过氧化物酶体增殖物激活受体γ共激活因子1α(PGC1-α)为桂枝甘草汤抗寒作用的关键靶点,甘草查尔酮D、欧甘草素A和肉桂酸为关键化合物。米格列醇组和桂枝甘草汤中、高剂量组血清总胆固醇水平低于空白对照组(P<0.05),桂枝甘草汤高剂量组血清甘油三酯水平低于空白对照组(P<0.05)。棕色脂肪组织中,高剂量桂枝甘草汤组线粒体膜电位低于冷暴露模型组(P<0.05);米格列醇组和高剂量桂枝甘草汤组ATP含量低于空白对照组(P<0.05);桂枝甘草汤各剂量组PPARγ蛋白表达高于冷暴露模型组(P<0.05),桂枝甘草汤中、高剂量组UCP1蛋白表达高于冷暴露模型组(P<0.05)。结论 桂枝甘草汤可提高冷暴露小鼠的核心体温,并减轻寒冷暴露所致的运动能力下降和外周组织损伤;其作用可能与激活BAT中PPARγ/UCP1信号通路、增强非寒颤产热有关,提示桂枝甘草汤具有潜在的抗寒应用价值。

关键词: 桂枝甘草汤;抗寒活性;脂肪组织, 棕色;PPARγ/UCP1 通路;网络药理学;产热

Abstract: Background Guizhi Gancao Decoction (GGD), a renowned formula in traditional Chinese medicine (TCM), comprises two medicinal herbs, Ramulus Cinnamomi (RC) and Radix Glycyrrhizae (RG). These herbs are believed to generate and strengthen the Yang energy, potentially exhibiting thermogenic properties. Objective To investigate the cold-protective activity of GGD, identify its main components, and further explore its mechanism based on brown adipose tissue (BAT). Methods The experiments were conducted from 2020 to 2023. GGD was prepared according to the method recorded in Shanghan Lun. Mice were randomized into six groups (n = 10): control (no cold exposure), model (cold exposure), miglitol (50 mg/kg, cold exposure), and three GGD groups (1, 2, 4 g/kg, cold exposure). After 14-day administration, mice were subjected to acute cold exposure (-20 ℃ , 60 min) and cold-adapted exposure (-20 ℃ , 120 min). Core body temperature and body surface temperature were measured using a digital rectal thermometer and an infrared thermal imaging camera. Motor performance was assessed by runway crossing time and swimming distance. Peripheral circulation protection was evaluated by tail non-necrotic length. Main components of GGD were identified by HPLC-Q-TOF-MS, and network pharmacology was used to predict key targets and pathways. Mechanistic validation was performed by Western blotting, mitochondrial membrane potential, and ATP content assays. Results After 60 min of acute cold exposure at -20 ℃ , core body temperature was significantly higher in the medium- and high-dose GGD groups than in the model group (P<0.05); after 120 min of exposure in cold-acclimated mice, core body temperature was significantly higher in all GGD groups than in the model group (P<0.05). Before cold exposure, there were no significant differences among groups in runway crossing time or swimming distance (P>0.05). After cold exposure, runway crossing time was significantly longer in the model and miglitol groups than in the control group; it was significantly shorter in the miglitol group and all GGD groups than in the model group, and significantly shorter in all GGD groups than in the miglitol group (all P<0.05). In the swimming test, swimming distance was significantly shorter in the model, miglitol, low-dose GGD, and medium-dose GGD groups than in the control group (P<0.05), whereas no significant differences were observed in the remaining pairwise comparisons (P>0.05). The non-necrotic tail length was significantly longer in the miglitol group and all GGD groups than in the model group (P<0.05). HPLC-Q-TOF-MS identified 49 compounds in GGD. Network pharmacology analysis suggested that PPARγ, UCP1, and PGC1-α were key targets of the anti cold effects of GGD, and that licochalcone D, hispaglabridin A, and cinnamic acid were key compounds. Serum total cholesterol levels were significantly lower in the miglitol group and the medium- and high-dose GGD groups than in the control group (P<0.05), and serum triglyceride levels were significantly lower in the high-dose GGD group than in the control group (P<0.05). In brown adipose tissue, mitochondrial membrane potential was significantly lower in the high-dose GGD group than in the model group (P<0.05); ATP content was significantly lower in the miglitol and high-dose GGD groups than in the control group (P<0.05); PPARγ protein expression was significantly higher in all GGD groups than in the model group (P<0.05), while UCP1 protein expression was significantly higher in the medium- and high-dose GGD groups than in the model group (P<0.05). Conclusion GGD increases core body temperature in cold-exposed mice and attenuates cold-induced impairment of motor performance and peripheral tissue injury. These effects may be associated with activation of the PPARγ/UCP1 signaling pathway in brown adipose tissue and enhancement of non-shivering thermogenesis, suggesting the potential of GGD for anti-cold applications.

Key words: Guizhi Gancao Decoction, Anti-cold activity, Adipose tissue, brown, PPARγ/UCP1 signaling pathway, Network pharmacology, Thermogenesis

中图分类号: